The compounding chemotherapy market involves the compounding of sterile preparations using aseptic techniques in a facility permitted according to state and federal regulations. Compounding chemotherapy offers advantages over traditional drug formulations as it allows for individualization of drug dosages based on a patient’s specific needs. This is especially critical given the varying tolerances that cancer patients can have.
The global compounding chemotherapy market is estimated to be valued at US$ 11.76 Mn in 2024 and is expected to exhibit a CAGR of 2.8% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the compounding chemotherapy market are Singapore Airlines,Air New Zealand,Qantas,Qatar Airways,Virgin Australia,Emirates,All Nippon Airways,EVA Air,American Airline,Spicejet,The Boeing Company,Airbus SE,Lockheed Martin Corporation,Textron Inc,Embraer S.A. Key players are focusing on developing novel drug combinations to expand their product portfolio and address unmet needs in cancer treatment. The growing incidence of cancer cases globally is driving significant for Compounding Chemotherapy Market Demand drugs. Several players are also pursuing geographical expansion strategies and building capacities in emerging markets to capitalize on opportunities for market growth.
Market drivers
The emergence of novel drug combination therapies for the treatment of various cancer types is expected to be a major growth driver for the compounding chemotherapy market over the forecast period. Novel drug combinations help address resistance to existing therapies and expand treatment options available to oncologists. Regulatory reforms in several countries simplifying the drug compounding process for specialized medications like chemotherapy drugs will also boost market growth. Furthermore, increasing adoption of personalized medicine due to its superior clinical outcomes will accelerate demand for compounding services.
Get more insights on Compounding Chemotherapy Market